MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers

//MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers

There are numerous reasons for immunotherapy to fail or for cancer in general to be able to fight against your body and survive. One important mechanism is Myeloid Derived Suppressor Cells (MDSC). These are immune cells that can actually protect cancer. As described in this article, a new method to target these using a drug that is already FDA approved (Mylotarg) can enhance the success of immunotherapy such as immune check-point inhibitors (Keytruda, Opdivo, Yervoy) and also CAR-.

More on https://www.sciencedirect.com/science/article/pii/S235239641930547X?via%3Dihub&amp=1&fbclid=IwAR1b1xMRrG8JeUe7GyI8UBfws8oED40RVwtFV5L1HRIFg_TgFW7QPnaqmjY

By | 2019-09-02T09:07:50-05:00 September 2nd, 2019|immunotherapy|0 Comments

Leave A Comment